About
This forum is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.
The programmes are free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.
Podcasts
Author Interview: Rebecca Haberman
Publications
Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate
Publications
Can Patients with Controlled Rheumatoid Arthritis Taper Methotrexate From Targeted Therapy and Sustain Remission? A Systematic Review and Meta-analysis
Publications
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
Publications
Treatment Persistence of Tumour Necrosis Factors And IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis
Publications
Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases
Publications
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Publications
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
Publications
Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a Randomized Phase IIb Study of Abatacept in Psoriatic Arthritis
Publications
Real-world Treatment Patterns and Use of Adjunctive Pain and Anti-inflammatory Medications Among Patients with Psoriatic Arthritis Treated With IL-17A Inhibitors In The United States
Publications
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
Publications
Deucravacitinib in Moderate-to-severe Psoriasis
Publications
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
Publications
Efficacy and Safety of Non-Pharmacological and Non-Biological Interventions: A Systematic Literature Review Informing the 2022 Update of the ASAS/EULAR Recommendations for the Management of AxSpA
Publications
ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis: 2022 Update
Publications
Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
Publications
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
Publications
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Publications
Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study
Publications
The Incidence of Opportunistic Infections in Patients with Psoriatic Arthritis Treated with Biologic and Targeted Synthetic Agents: A Systematic Review and Meta-analysis
Publications
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 52-week Results from the Keepsake 2 Study
Publications
Efficacy And Safety of Risankizumab for Active Psoriatic Arthritis: 52-Week Results from the Keepsake 1 Study
Publications
Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients with Psoriasis or Psoriatic Arthritis
Publications
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
Publications
Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients with Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results from the Randomized SPIRIT-H2H Trial
Publications
Comparative Performance of Composite Measures From Two Phase III Clinical Trials of Ixekizumab in Psoriatic Arthritis
Publications
Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to A Systematic Literature Review and Network Meta-analysis
Publications
Toxicity Signals Associated with Secukinumab: A Pharmacovigilance Study Based on The United States Food And Drug Administration Adverse Event Reporting System Database
Publications
Risk of MACE with Tofacitinib Versus TNFi in Patients with RA With or Without a History of Atherosclerotic CV: A Post Hoc Analysis from ORAL Surveillance
Publications
Venous Thromboembolism with JAK Inhibitors and Other Immune-Modulatory Drugs: a Swedish Comparative Safety Study Among Patients with Rheumatoid Arthritis
Breaking News
Galapagos Receives Positive CHMP Opinion for Filgotinib European Label Update Based on Testicular Function Safety Data
Publications